Summit Therapeutics (SMMT) Stock Price, News & Analysis

Company Overview

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration. Alongside its infectious disease program, Summit has explored small‐molecule therapies for rare genetic disorders, leveraging its drug discovery capabilities to identify compounds that modulate disease‐relevant pathways.

Founded in 2003 and headquartered in Oxford, England, Summit maintains operations in North America to support clinical development and regulatory activities across the United States and Europe. The company’s management team brings extensive experience in biopharmaceutical research, clinical operations, and commercialization strategy, with a commitment to advancing its pipeline toward regulatory approval and broad patient access.

Key Stats

• Today's Range: $23.30 to $24.29
• 50-Day Range: $20.60 to $29.32
• 52-Week Range: $11.76 to $36.91
• Volume: 3.12 million shs
• Average Volume: 3.07 million shs
• Market Capitalization: $17.47 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.31
• Consensus Rating: Moderate Buy

Summit Therapeutics Stock Analysis - MarketRank™

Summit Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 400th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Summit Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 11 buy ratings, 1 hold rating, and 3 sell ratings.

Amount of Analyst Coverage

Summit Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Summit Therapeutics are expected to decrease in the coming year, from ($0.30) to ($0.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Summit Therapeutics is -23.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Summit Therapeutics is -23.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Summit Therapeutics has a P/B Ratio of 67.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.01% of the outstanding shares of Summit Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Summit Therapeutics has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Summit Therapeutics has recently decreased by 3.81%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Summit Therapeutics does not currently pay a dividend.

Dividend Growth

Summit Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.01% of the outstanding shares of Summit Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Summit Therapeutics has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Summit Therapeutics has recently decreased by 3.81%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.90

News Sentiment

Summit Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Summit Therapeutics this week, compared to 8 articles on an average week.

Search Interest

24 people have searched for SMMT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Summit Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

84.90% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 4.61% of the stock of Summit Therapeutics is held by institutions.

SMMT Stock Analysis - Frequently Asked Questions

How have SMMT shares performed this year?

Summit Therapeutics' stock was trading at $17.84 at the beginning of 2025. Since then, SMMT stock has increased by 31.8% and is now trading at $23.52.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics PLC (NASDAQ:SMMT) released its quarterly earnings results on Monday, August, 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.66.

When did Summit Therapeutics IPO?

Summit Therapeutics (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' top institutional shareholders include State Street Corp (0.54%), Geode Capital Management LLC (0.40%), Norges Bank (0.19%) and APEIRON CAPITAL Ltd (0.16%). Insiders that own company stock include Robert W Duggan, Ankur Dhingra and Mahkam Zanganeh.
View institutional ownership trends.

How do I buy shares of Summit Therapeutics?

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SMMT
• CIK: 1599298
• Web: www.summitplc.com
• Phone: 650-460-8308
• Fax: 44-12-3544-3999
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Summit Therapeutics: $33.31
• High Price Target: $50.00
• Low Price Target: $12.00
• Potential Upside/Downside: +41.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$221.32 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -208.64%
• Return on Assets: -181.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.13
• Quick Ratio: 5.13

Sales & Book Value

• Annual Sales: $700 thousand
• Price / Sales: 24,959.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 67.20

Miscellaneous

• Outstanding Shares: 742,850,000
• Free Float: 112,170,000
• Market Cap: $17.47 billion
• Optionable: Optionable
• Beta: -1.02